HCMT
OCUL icon

Highland Capital Management (Tennessee)’s Ocular Therapeutix OCUL Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,000
Closed -$69K – 325
2020
Q1 		$69K Hold
14,000
– – 0.01% 293
2019
Q4 		$55K Hold
14,000
– – ﹤0.01% 308
2019
Q3 		$43K Hold
14,000
– – ﹤0.01% 302
2019
Q2 		$62K Buy
+14,000
New +$51.8K ﹤0.01% 297

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Highland Capital Management (Tennessee)'s OCUL Position: Q2 2020 in Review

Highland Capital Management (Tennessee) sold out of Ocular Therapeutix (OCUL) in Q2 2020, closing a stake of 14,000 shares — an estimated $69K sold.

Highland Capital Management (Tennessee) first reported a position in OCUL in Q2 2019 and held it in 4 quarters. The position peaked at $69K in Q1 2020. 106 funds tracked by Wall St. Rank hold OCUL as of Q2 2020.

  • Highland Capital Management (Tennessee) reported no remaining Ocular Therapeutix position as of Q2 2020 after selling out during the quarter.
  • Highland Capital Management (Tennessee) sold 14,000 Ocular Therapeutix shares in Q2 2020, an estimated $69K.
  • Highland Capital Management (Tennessee) first reported a position in Ocular Therapeutix in Q2 2019 and held it in 4 quarters.
  • Highland Capital Management (Tennessee)'s Ocular Therapeutix position peaked at $69K in Q1 2020.
  • 106 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2020.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2020, filed 22 Jul 2020.